| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.07▼ | 2.07▼ | 2.06▼ | 1.99▲ | 2.70▼ |
| MA10 | 2.08▼ | 2.05▼ | 2.00▲ | 2.20▼ | N/A |
| MA20 | 2.08▼ | 1.99▲ | 1.98▲ | 2.95▼ | N/A |
| MA50 | 2.04▼ | 1.99▲ | 2.03▲ | N/A | N/A |
| MA100 | 1.98▲ | 2.03▼ | 2.64▼ | N/A | N/A |
| MA200 | 1.99▲ | 2.74▼ | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.008▼ | 0.011▲ | 0.025▲ | N/A | N/A |
| RSI | 37.294▼ | 54.838▲ | 51.396▲ | 24.807▼ | N/A |
| STOCH | 32.639 | 80.398▲ | 89.572▲ | 9.317▼ | N/A |
| WILL %R | -100.000▼ | -35.556 | -34.783 | -92.990▼ | N/A |
| CCI | -247.619▼ | 43.350 | 85.382 | -54.247 | N/A |
|
Thursday, May 21, 2026 09:03 PM
NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other ...
|
|
Thursday, May 21, 2026 01:39 PM
The Base Shelf Prospectus is, and the Prospectus Supplement will be accessible within two business days, through SEDAR+VANCOUVER, British ...
|
|
Tuesday, May 19, 2026 11:19 AM
NervGen Pharma ( (NGEN)) has provided an announcement. NervGen Pharma reported first-quarter 2026 results on May 18, highlighting progress on NVG-291 and its transition to a U.S.-focused capital ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 04/06/26 | 1.93 | 2.12 | 1.92 | 2.01 | 1,214,023 |
| 03/06/26 | 1.99 | 2.01 | 1.87 | 1.91 | 1,147,077 |
| 02/06/26 | 1.92 | 2.04 | 1.9099 | 2.00 | 627,812 |
| 01/06/26 | 2.08 | 2.10 | 1.91 | 1.94 | 1,145,215 |
| 29/05/26 | 2.12 | 2.13 | 2.04 | 2.07 | 967,533 |
| 28/05/26 | 2.10 | 2.11 | 2.055 | 2.08 | 1,134,421 |
| 27/05/26 | 2.15 | 2.15 | 2.05 | 2.07 | 1,485,194 |
| 26/05/26 | 2.21 | 2.21 | 1.98 | 2.13 | 5,783,818 |
| 22/05/26 | 2.24 | 2.25 | 2.02 | 2.08 | 12,409,441 |
| 21/05/26 | 3.73 | 3.73 | 3.62 | 3.68 | 49,332 |
|
|
||||
|
|
||||
|
|